Top

Published in:

01-06-2011 | Research Paper

Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells

Authors: Steffen Wedel, Lukasz Hudak, Jens-Michael Seibel, Jasmina Makarević, Eva Juengel, Igor Tsaur, Christoph Wiesner, Axel Haferkamp, Roman A. Blaheta

Published in: Clinical & Experimental Metastasis | Issue 5/2011

Abstract

The concept of molecular tumor targeting might provide new hope in the treatment of advanced prostate cancer. We evaluated metastasis blocking properties of the histone deacetylase (HDAC) inhibitor valproic acid (VPA) and the mammalian target of rapamycin (mTOR) inhibitor RAD001 on prostate cancer cell lines. RAD001 or VPA were applied to PC-3 or LNCaP cells, either separately or in combination. Adhesion to vascular endothelium or to immobilized collagen, fibronectin or laminin was quantified. Migration and invasion were explored by a modified Boyden chamber assay. Integrin α and β subtypes were analyzed by flow cytometry, western blotting and RT-PCR. Effects of drug treatment on integrin related signaling, Akt and p70S6kinase activation, histone H3 and H4 acetylation were also determined. Separate application of RAD001 or VPA distinctly reduced tumor cell adhesion, migration and invasion, accompanied by elevated Akt activation and p70S6kinase de-activation. Integrin subtype expression was altered significantly by both compounds (VPA > RAD001). When both drugs were used in concert additive effects were observed on the migratory and invasive behavior but not on tumor-endothelium and tumor-matrix interaction. Separate mTOR or HDAC inhibition slows processes related to tumor metastasis. The RAD001-VPA combination showed advantage over VPA monotreatment with particular respect to migration and invasion. Ongoing studies are required to assess the relevance of VPA monotherapy versus VPA-RAD001 combination on tumor cell motility.

Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96PubMedCrossRef

Ward JF, Moul JW (2005) Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol 2:174–182PubMedCrossRef

Han M, Partin AW, Pound CR et al (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28:555–565PubMedCrossRef

Wang L, Zou X, Berger AD et al (2009) Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res 1:62–71PubMed

Weichert W, Röske A, Gekeler V et al (2008) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98:604–610PubMedCrossRef

Halkidou K, Gaughan L, Cook S et al (2004) Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59:177–189PubMedCrossRef

Kremer CL, Klein RR, Mendelson J et al (2006) Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66:1203–1212PubMedCrossRef

Dai B, Kong YY, Ye DW et al (2009) Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int 104:1009–1016PubMedCrossRef

Bedolla R, Prihoda TJ, Kreisberg JI et al (2007) Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 13:3860–3867PubMedCrossRef

10.

Shimizu Y, Segawa T, Inoue T et al (2007) Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. BJU Int 100:685–690PubMedCrossRef

11.

Angelucci A, Muzi P, Cristiano L et al (2008) Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma. Prostate 68:588–598PubMedCrossRef

12.

Shabbeer S, Kortenhorst MS, Kachhap S et al (2007) Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 67:1099–1110PubMedCrossRef

13.

Xia Q, Sung J, Chowdhury W et al (2006) Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 66:7237–7244PubMedCrossRef

14.

Morgan TM, Pitts TE, Gross TS et al (2008) RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 68:861–871PubMedCrossRef

15.

Schayowitz A, Sabnis G, Njar VC et al (2008) Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Mol Cancer Ther 7:121–132PubMedCrossRef

16.

Iiizumi M, Mohinta S, Bandyopadhyay S et al (2007) Tumor-endothelial cell interactions: therapeutic potential. Microvasc Res 74:114–120PubMedCrossRef

17.

Hall CL, Dai J, van Golen KL et al (2006) Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res 66:8648–8654PubMedCrossRef

18.

Van Slambrouck S, Jenkins AR, Romero AE et al (2009) Reorganization of the integrin alpha2 subunit controls cell adhesion and cancer cell invasion in prostate cancer. Int J Oncol 34:1717–1726PubMed

19.

Liu JM, Bignon J, Haroun-Bouhedja F et al (2005) Inhibitory effect of fucoidan on the adhesion of adenocarcinoma cells to fibronectin. Anticancer Res 25:2129–2133PubMed

20.

Chao WT, Kunz J (2009) Focal adhesion disassembly requires clathrin-dependent endocytosis of integrins. FEBS Lett 583:1337–1343

21.

Oertl A, Relja B, Makarevic J et al (2006) Altered expression of beta1 integrins in renal carcinoma cell lines exposed to the differentiation inducer valproic acid. Int J Mol Med 18:347–354PubMed

22.

Björkman M, Iljin K, Halonen P et al (2008) Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer 123:2774–2781PubMedCrossRef

23.

Nagakawa O, Akashi T, Hayakawa Y et al (2004) Differential expression of integrin subunits in DU-145/AR prostate cancer cells. Oncol Rep 12:837–841PubMed

24.

Welsbie DS, Xu J, Chen Y et al (2009) Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 69:958–966PubMedCrossRef

25.

Slack-Davis JK, Parsons JT (2004) Emerging views of integrin signaling: implications for prostate cancer. J Cell Biochem 91:41–46PubMedCrossRef

26.

Schmelz M, Cress AE, Scott KM et al (2002) Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cell-extracellular adhesion sites. Neoplasia 4:243–254PubMedCrossRef

27.

Lai TH, Fong YC, Fu WM et al (2008) Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins. Prostate 68:1341–1353PubMedCrossRef

28.

Wang X, Ferreira AM (2005) Shao Q et al. (2005) Beta3 integrins facilitate matrix interactions during transendothelial migration of PC3 prostate tumor cells. Prostate 63:65–80PubMedCrossRef

29.

Balasubramanian S, Kuppuswamy D (2003) RGD-containing peptides activate S6K1 through beta3 integrin in adult cardiac muscle cells. J Biol Chem 278:42214–42224PubMedCrossRef

30.

Priulla M, Calastretti A, Bruno P et al (2007) Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate 67:782–789PubMedCrossRef

31.

Verheul HM, Salumbides B, Van Erp K et al (2008) Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 14:3589–3597PubMedCrossRef

32.

Mahalingam D, Medina EC, Esquivel JA 2nd et al (2010) Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res 16:141–153PubMedCrossRef

33.

Taliaferro-Smith L, Nagalingam A, Zhong D et al (2009) LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene 28:2621–2633PubMedCrossRef

34.

Chen CS, Weng SC, Tseng PH et al (2005) Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280:38879–38887PubMedCrossRef

35.

Ridolfi E, Matteucci E, Maroni P et al (2008) Inhibitory effect of HGF on invasiveness of aggressive MDA-MB231 breast carcinoma cells, and role of HDACs. Br J Cancer 99:1623–1634PubMedCrossRef

36.

Lydolph MC, Morgan-Fisher M, Høye AM et al (2009) Alpha9beta1 integrin in melanoma cells can signal different adhesion states for migration and anchorage. Exp Cell Res 315:3312–3324PubMedCrossRef

37.

Lakshman M, Xu L, Ananthanarayanan V et al (2008) Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res 68:2024–2032PubMedCrossRef

38.

Russell MR, Jamieson WL, Dolloff NG, Fatatis A (2009) The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Oncogene 28:412–421PubMedCrossRef

Title: Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells
Authors: Steffen Wedel
Lukasz Hudak
Jens-Michael Seibel
Jasmina Makarević
Eva Juengel
Igor Tsaur
Christoph Wiesner
Axel Haferkamp
Roman A. Blaheta
Publication date: 01-06-2011
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 5/2011
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-011-9386-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2011

Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERα negative breast cancer cell lines

Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature

Identification of annexin A1 as a proinvasive and prognostic factor for lung adenocarcinoma

Role of DDR1 in the gelatinases secretion induced by native type IV collagen in MDA-MB-231 breast cancer cells

Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors

Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity

Keynote webinar | Spotlight on antibody–drug conjugates in cancer